Nanobiotix Stock Falls Nearly 5% in a Sluggish Market
The Paris-based biotech is posting one of the most marked declines in the French market on Wednesday, ranking among the strongest falls of the SBF 120 in an already deteriorated index context. The security broke through its intraday support level and is moving further away from its short-term moving averages, extending a difficult sequence that began several weeks ago.
A Broken Support Level Amplifying the Weekly and Monthly Decline of the Security
Nanobiotix is down 4.86% in trading, at 30.92 €, after breaching its support level of 32.30 € on the downside without recovering it. This is the most unfavorable technical configuration: the threshold that had served as support for several trading sessions has given way, leaving the price without an identified floor in the short term before the next support zone. The decline adds to an already red week (−7.7% over seven days) and a difficult month (−7.59% over thirty days), although the security maintains an exceptional gain of +312.3% over one year.
The SBF 120 is also down 1.82% in trading, but the magnitude of Nanobiotix's decline far exceeds that of the index, placing the security at rank 119 out of 120 members. In this context of market tension, the VIX rises to 16.49, up 7.78% compared to the previous day.
Two Short-Term Moving Averages as Resistance Levels, the 200-Day MA Remains a Notable Cushion
The price is trading below the 20-day MA (34.98 €), with a gap of −11.61%, and below the 50-day MA (34.33 €), with a gap of −9.93%: the two short-term moving averages now act as resistance levels, a configuration that weighs on momentum. Conversely, the price remains above the 200-day MA, at 27.72 €, with a gap of +11.54%, which testifies to the strength of the upward trend initiated over one year despite recent turbulence. The RSI at 45 remains in neutral territory, with no oversold signal, indicating that selling pressure has not yet been exhausted.
The next significant resistance is located at 38.60 €, representing a potential rebound of approximately 25% from the current price. The stock is also listed on the Nasdaq in the form of an ADS (ticker NBTX), with a one-to-one ratio, the two lines being closely correlated; eligibility for the PEA remains reserved for the ordinary share on Euronext Paris.
